Read More Pharma Industry News Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant… byPallavi MadhirajuSeptember 2, 2023